Avadel Pharmaceuticals

Yahoo Finance • 3 months ago

Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent

Avadel Pharmaceuticals plc – Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and were not using a stable dose of an alerting agent – – Baseline data underscore that ale... Full story

Yahoo Finance • 8 months ago

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

Avadel Pharmaceuticals plc -- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients initiated the... Full story

Yahoo Finance • 8 months ago

11 Best Low Price Pharma Stocks To Invest In

In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Be... Full story

Yahoo Finance • 11 months ago

Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights

Avadel Pharmaceuticals plc -- Approximately $19 million and $28 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter and full year 2023, respectively -- -- Generated continued robust demand for LUMRYZ with greate... Full story

Yahoo Finance • last year

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

-- $7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch -- -- Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUPTM and more than 400 patients initiating therapy as of September 3... Full story

Yahoo Finance • last year

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate i... Full story

Yahoo Finance • last year

Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 8

DUBLIN, Ireland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live... Full story

Yahoo Finance • last year

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023

– 17 abstracts accepted, including new and encore data emphasizing clinical benefit and patient preference for a once-at-bedtime narcolepsy treatment option – – Company to host symposium on October 24 with leading KOLs discussing evolutio... Full story

Yahoo Finance • last year

Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit

DUBLIN, Ireland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate i... Full story

Yahoo Finance • last year

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors... Full story

Yahoo Finance • 2 years ago

Jazz Pharmaceuticals Sues FDA Over Approval Of Rival Product, Calls It 'Unlawful'

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has filed suit against the FDA for approving Avadel Pharmaceuticals Plc's (NASDAQ: AVDL) Lumryz (sodium oxybate extended-release) for cataplexy or excessive daytime sleepiness in adult patients with... Full story

Yahoo Finance • 2 years ago

Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII

DUBLIN, Ireland, June 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a Commercial Day presentati... Full story

Yahoo Finance • 2 years ago

Avadel Pharmaceuticals Sponsors the Academy of Sleep Medicine Foundation’s 2023 Young Investigators Research Forum

DUBLIN, Ireland, June 14, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced leader sponsorship of the American Academy of Sleep Medicine (A... Full story

Yahoo Finance • 2 years ago

Avadel Pharmaceuticals Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-at-Bedtime Oxybate Dosing for Narcolepsy

DUBLIN, Ireland, June 13, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the publication of survey data describing clinician preferences... Full story

Yahoo Finance • 2 years ago

Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy

- Granted Orphan Drug Exclusivity through May 1, 2030 - -Advanced commercial preparations on track; LUMRYZ product availability expected in early June - - Final approval supported by robust efficacy and safety data from pivotal Phase 3 R... Full story

Yahoo Finance • 2 years ago

Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference

DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate... Full story

Yahoo Finance • 2 years ago

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2022 Earnings Call Transcript

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2022 Earnings Call Transcript March 31, 2023 Operator: Greetings, and welcome to Avadel Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Call. It is now my pleasure to introduce Austin... Full story

Yahoo Finance • 2 years ago

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

• LUMRYZ™ NDA amendment filed March 1 requesting FDA final approval • Received FDA authorization to import LUMRYZ in advance of final approval decision; shortens timeline between potential approval and product availability • Secured $200... Full story

Yahoo Finance • 2 years ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live... Full story

Yahoo Finance • 2 years ago

Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the pricing of an underwritten pu... Full story